Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress

Timea Aczél1†, Bettina Benczik2,3†, Bence Ágg2,3, Tamás Körtési4,5, Péter Urbán6, Witold Bauer6, Attila Gyanesei6, Bernadett Tuka4,5, János Tajti7, Péter Ferdinandy2,3, László Vécsei4,7, Kata Bölcskei1, József Kun1,6† and Zsuzsanna Helyes1,8,9†

Abstract

Background: Migraine is a primary headache with genetic susceptibility, but the pathophysiological mechanisms are poorly understood, and it remains an unmet medical need. Earlier we demonstrated significant differences in the transcriptome of migraineurs’ PBMCs (peripheral blood mononuclear cells), suggesting the role of neuroinflammation and mitochondrial dysfunctions. Post-transcriptional gene expression is regulated by miRNA (microRNA), a group of short non-coding RNAs that are emerging biomarkers, drug targets, or drugs. MiRNAs are emerging biomarkers and therapeutics; however, little is known about the miRNA transcriptome in migraine, and a systematic comparative analysis has not been performed so far in migraine patients.

Methods: We determined miRNA expression of migraineurs’ PBMC during (ictal) and between (interictal) headaches compared to age- and sex-matched healthy volunteers. Small RNA sequencing was performed from the PBMC, and mRNA targets of miRNAs were predicted using a network theoretical approach by miRNAtarget.com™. Predicted miRNA targets were investigated by Gene Ontology enrichment analysis and validated by comparing network metrics to differentially expressed mRNA data.

Results: In the interictal PBMC samples 31 miRNAs were differentially expressed (DE) in comparison to healthy controls, including hsa-miR-5189-3p, hsa-miR-96-5p, hsa-miR-3613-5p, hsa-miR-99a-3p, hsa-miR-542-3p. During headache attacks, the top DE miRNAs as compared to the self-control samples in the interictal phase were hsa-miR-3202, hsa-miR-7855-5p, hsa-miR-6770-3p, hsa-miR-1538, and hsa-miR-409-5p. MiRNA-mRNA target prediction and pathway analysis indicated several mRNAs related to immune and inflammatory responses (toll-like receptor and cytokine receptor signalling), neuroinflammation and oxidative stress, also confirmed by mRNA transcriptomics.
Conclusions: We provide here the first evidence for disease- and headache-specific miRNA signatures in the PBMC of migraineurs, which might help to identify novel targets for both prophylaxis and attack therapy.

Keywords: Migraine, miRNA, Peripheral blood mononuclear cells, Cytokines, Oxidative stress, Human

Introduction

Migraine is a common primary headache disease with complex pathophysiological mechanisms. This neurovascular disorder involves meningeal vasodilatation, oedema formation activation and sensitisation of the trigeminal pain pathways [1]. Immune activation and the release of proinflammatory cytokines and neuropeptides, such as CGRP (calcitonin gene-related peptide) and PACAP (pituitary adenylate cyclase-activating polypeptide), seem to be critical elements [2–6]. Besides genetic factors, environmental influence has been described for migraine susceptibility [7]. There has not been a breakthrough in effective personalised preventive or acute treatment of migraine despite extensive efforts. It is still an unmet medical need mainly due to the heterogeneity of the disease. Therefore, it is essential to explore the complexity of the pathophysiological mechanisms by unbiased omics approaches. PBMCs, containing lymphocytes (T cells, B cells, natural killer cells) and monocytes, have become attractive blood-based marker candidates in clinical practice due to minimally invasive sampling and relatively simple isolation. Their potential value consists of reflecting pathophysiological changes in the central nervous system in various diseases. Hence neuroinflammatory processes might be studied in a specific way using PBMCs [8–10]. We have recently provided evidence for increased immune cell activity, oxidative stress and mitochondrial dysfunction in migraine using transcriptomics of peripheral blood mononuclear cells (PBMC) [11]. MicroRNAs (miRNAs) are short, non-coding RNAs regulating post-transcriptional gene expression, and thus controlling cell-to-cell communication and multiple cellular processes. [12–14]. Since miRNAs can reflect the environmental impact on gene expression modulation [15], their relevance in preclinical research and clinical applications is rapidly growing. Circulating miRNAs are stable, easily measurable and tissue-specific molecules [13, 16]; therefore, they receive increased attention as tissue-specific biomarkers for various pathological processes, drug resistance modulators, and novel drug targets. Several clinical studies suggest specific miRNAs to be indicators of disease progression, e.g. in diabetes, coronary heart disease, breast cancer, epilepsy, depressive disorder, stroke, etc. [16]. Interestingly, miRNAs can interfere with immune, vascular, and neuronal activities [17–19]. Thus, they might be valuable in neuro-immune-vascular interactions and alterations like neuropathic pain, Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine [20]. Their relevance in chronic pain conditions, e.g. complex regional pain syndrome, irritable bowel syndrome and fibromyalgia, have also been studied [21, 22].

Detection of miRNAs in molecular research and diagnostics is fundamental as well as challenging due to their low cell content, small size, and the similar sequences of miRNA families. Continuous development has yielded detection methods ranging from conventional techniques such as microarrays and PCR (polymerase chain reaction) to the more recent next-generation sequencing. MicroRNA microarray is a technique for miRNA profiling utilizing hybridization between target miRNAs and their corresponding complementary probes on a solid surface and eventual detection of the signal intensity of the hybridization probes. It has high throughput although low sensitivity and selectivity. PCR, on the other hand, has high sensitivity, a wider range but poor specificity for miRNAs, along with limited throughput. RNA-seq represents the last extensive approach for miRNA profiling. Its workflow involves the isolation of RNA followed by cDNA (complementary DNA) library construction and sequencing. Small RNA-Seq was chosen for our study based on its main advantages of having a non-targeted and greatly sensitive nature [23, 24].

The potential roles of miRNAs in migraine diagnosis and therapy have recently been reviewed, but the clinical relevance of the results needs to be clarified and confirmed [25, 26]. Few investigations have been performed on specific miRNAs [16–19] and microarray-based miRNA profile descriptions, with controversial results [27–29]. One study describes serum miRNA alterations both during attacks and pain-free periods of migraineurs, using high-content serum microRNA PCR arrays [27]. In contrast, no alterations were described in the miRNA profiles of 20 mixed gender migraine patients’ PBMC samples compared to 5 headache-free controls in a conference abstract [29]. The extension of this pilot study (MicroMIG) demonstrated a few DE miRNAs when comparing different
subgroups of migraine patients to controls, but they were not specified [30]. Two-sample microarray analysis of exosomes isolated from pooled blood samples of 15 female migraineurs without aura compared to 13 healthy matched controls described 22 dysregulated circulating miRNAs, 4 of which were validated by qPCR. MiR-22 and let-7b downregulation was confirmed in PBMC samples [28]. PBMCs represent an easily accessible biological material, which can reflect pathophysiological changes in the brain and characterize neuroinflammatory processes [8, 9]. Therefore, here we determine miRNAs from PBMC samples to gather more information on disease- and headache-related mechanisms in migraineurs since their transcriptomic alterations were proven to be specific and sensitive indicators of migraine-related processes [11]. To our knowledge, this is the first study to perform small RNA sequencing on PBMCs isolated from interictal and ictal samples of migraine patients compared with healthy controls. Combining network theoretical miRNA-target prediction and an already analyzed mRNA data set provides a unique and valuable platform for discovering potential novel biomarkers and/or drug targets in migraine.

**Methods**

**Study design**

The study was approved by the National Public Health Center, Ministry of Human Capacities (28324–5/2019/EÜIG). Informed written consent was obtained from each participant following the Declaration of Helsinki.

Sixteen episodic migraine patients with \((n = 1)\) or without aura \((n = 15)\) and 12 healthy controls, aged between 23 and 59 years, were enrolled in the present study. Out of the 16 migraineurs, 8 patients applied for blood sampling during headache attacks (one patient applied twice). Therefore, 9 ictal (self-controlled paired) samples were further investigated. In total, 37 samples from 28 participants were selected from the cohort collected between September 2018 and December 2019. The inclusion criteria were female gender, aged 20–60 years, diagnosed with migraine with or without aura by the third edition of the International Classification of Headache Disorders [31]. Exclusion criteria were chronic inflammatory diseases and depression. A detailed questionnaire was used to assess the characteristics of the headache concerning the following: prophylactic or attack medication before sampling, the number of attacks in the previous month, the time of the last episode, the beginning of the current attack, other known diseases, applied drugs and contraceptives, the relation of migraine attacks to the menstrual cycle, the presence of allodynia, attack frequency, duration of migraine, severity of pain during attacks as measured on a visual analogue scale, comorbidities with other chronic diseases, the familial manifestation of migraine, regular sport activity and the time of the last meal were recorded, as described earlier [11]. Besides, patients were examined by Hamilton’s depression scale to exclude participants with an assessment of depression. There were no restrictions regarding food and drink intake. Blood samples were collected from migraine sufferers in an attack-free period and during an attack. Healthy controls were screened for non-reported/non-treated headaches and matched all demographic characteristics.

**Sample collection**

Human blood samples were collected from participants, after which processing started within 1 h. Tubes containing anticoagulant EDTA (ethylenediaminetetraacetic acid) were used for sample collection. PBMCs were isolated using Ficoll-Paque PREMIUM (GE Healthcare, Budapest, Hungary) according to the manufacturer’s instructions, as previously described [11]. After removing the liquid phase, cells were resuspended with 1 ml of TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) and stored at -80 °C until further investigations.

**RNA extraction and quality control**

Total RNA was extracted by applying the phenol–chloroform-based TRI Reagent procedure (Molecular Research Center, Cincinnati, OH, USA), followed by extraction and purification using the Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA). The manufacturer’s protocol was followed, including the optional on-column DNase digestion, as described earlier [11, 32]. RNA concentrations were measured with Qubit 3.0 (Invitrogen, Carlsbad, CA, USA), and quality was checked on TapeStation 4200 using RNA ScreenTape (Agilent Technologies, Santa Clara, CA, USA). High-quality (RIN > 8) RNA samples were further used for library preparation.

**Small RNA library preparation and sequencing**

Small RNA Libraries were generated using the SmallRNA-Seq Library Prep Kit (Lexogen, Vienna, Austria). Briefly, 200 ng of total RNA was used as input, and
3′ and 5′ adapters were ligated, followed by column purifications. Thereafter, the ligation products were reverse transcribed, and the input RNA, flanked by 5′ and 3′ adapters, were converted into cDNA. Finally, the libraries were amplified and barcoded using 16 cycles of PCR. All libraries were assessed on the TapeStation 4200 (Agilent Technologies, Santa Clara, CA, USA) to examine if adapter dimers formed during PCR. The libraries were sequenced on an Illumina NextSeq550 platform generating 75 bp single-end reads. All RNA-Seq datasets generated as part of this study will be publicly available at the European Nucleotide Archive (https://www.ebi.ac.uk/ena), under accession number PRJEB46142. A total of 37 blood samples were used for PBMC small RNA sequencing.

Bioinformatics – miRNA-Seq, miRNA target prediction, and miRNA-mRNA target network analysis

The sequenced reads were aligned against the Homo sapiens reference genome (GRCh37 Ensembl release) with STAR v2.5.3a [33]. After alignment, the reads were associated with known protein-coding genes, and the number of reads aligned within each gene was counted using Rsubread package v2.0.0 [34]. Gene count data were normalized using the TMM (trimmed mean of M values) normalization method of the edgeR R/Bioconductor package (v3.28, R v3.6.0, Bioconductor v3.9) [35]. The data were further log transformed using the voom approach [36] in the limma package [37] for statistical testing. Normalized counts were represented as TPM (transcripts per million) values. FC (fold change) values between the compared groups resulting from the linear modelling process and modified t-test p-values were produced by the limma package. The Benjamini–Hochberg method was used to control the FDR (False Discovery Rate), and adjusted p-values were calculated by limma. In the case of paired ictal and interictal samples, the correlation between samples originating from the same patient was taken into account using the duplicateCorrelation function of limma.

After statistical filtering for DE (differentially expressed) miRNAs in each comparison ([|FC|>1.2 and p<0.05), the DIANA-miRPath v3.0 web tool [38] was used to perform GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis (p<0.01) using the microTCDS predicted targets of the DE miRNA list for each comparison with default settings, accessed on November 12th, 2021. To highlight specific terms, GO BP terms with frequency values less than 0.15 were taken into account, where the frequency is defined as the proportion of gene products annotated by the selected GO term in the European Bioinformatics Institute Gene Ontology Annotation database for human. Higher frequency value implies more general terms, and lower implies more specific ones.

The network theoretical miRNAtarget.com™ software (mirnatarget.com; Pharmahungary, Szeged, Hungary) was used to predict target genes and their expected expression changes based on the lists of DE miRNAs. For this analysis, similarly to previous works [18, 19, 40–43], data from the manually curated, experimentally validated miRTarBase [44] (v7.0), the predicted miRDB [45] (v5.0 with score>80.0) and microRNA.org [46] (release of August 2010 with mirSVR score<-1.2), miRNA-target interaction databases were integrated by miRNAtarget. Positive and negative edge weights (1, -1) in the network, referring to predicted interaction with up- and down-regulated miRNAs, respectively, were summed to calculate node strength values, which estimate the extent of the predicted expression change of the targets. To achieve adequate visual representation of the information content of our networks, we used the EntOptLayout plugin [47] (version 2.1) for the Cytoscape [48] (version 3.7.2) software and further improved the visualisation by graphically highlighting node strength values. To elucidate the role of predicted target genes in biological processes, GO enrichment analysis [49, 50] was performed for each comparison, separately for up- and down-regulated targets. The online PANTHER Overrepresentation Test ([51], version released on July 28th, 2020) was used with default settings (Fisher’s Exact test with FDR calculation). From the GO Ontology Database ([52], version released on October 9th, 2020) Homo sapiens “GO biological process complete” annotation dataset was used for the analysis.

Validation of predictions at mRNA level based on RNA sequencing data

To validate the small RNA sequencing-based miRNA-target predictions at the mRNA level, we used mRNA-Seq data from our previous study [11]. We included samples from the same cohort mentioned above in the present investigation with minimal changes to ensure a more homogenous patient group. We validated the in silico predicted miRNA-target interactions at the mRNA level by matching the predicted mRNAs from the present study to the differentially expressed mRNAs from our previous study cited above. We compared the
predicted node strength values to the mRNA binary logarithm of the FC values with respect to the direction of changes. We considered genes to be validated that showed expression change consistent with the predictions.

Statistical analysis
The demographic and clinical characteristics of the studied population are presented in Table 1. Numerical data were summarized with their arithmetic means and 95% confidence intervals. Continuous parameters were tested for normality with Shapiro–Wilk’s tests and visual inspections. Homogeneity of variance across groups was studied using Levene’s tests. If the resulting p-values from these two tests were less than the significance level of 0.05, non-parametric tests were used for response variables. The differences between the mean values of each parameter and its distribution within the study population (migraineurs and healthy) were tested using the non-parametric Kruskal–Wallis rank-sum test or ANOVA (analysis of variance), if applicable followed by Benjamini–Hochberg multiple-testing correction. To compare the parameters between the migraineurs group and its two phases: interictal and ictal, paired-samples Wilcoxon test (or paired t-test, if applicable) was used. The statistical significance level was set at 0.05 for all two-sided tests. The data were analysed using R version 4.0.2.

Results
Clinical characteristics of the patient population
The patients’ demographic and main clinical features for the total number of 28 participants are provided in Table 1. The interictal group consists of 16 migraine patients, with blood sampling in a headache-free period. Ictal samples were collected from 8 of them for self-control comparison. The 12 control samples consisted of healthy volunteers. Demographic characteristics were similar across the subgroups. No significant alterations were found when comparing different subgroups' demographic and clinical characteristics, e.g. age, attack

Table 1 Description of the study subjects, main demographic, and clinical characteristics. Mean values (with 95% confidence intervals) of the selected parameters in migraineurs (interictal and ictal phase) and healthy control groups. Headache pain was evaluated with the VAS (visual analogue scale). Categories are as follows: 1–4 grade (1), 5–7 grade (2), 8–10 grade (3)

| Parameter                                                                 | Interictal (n = 16) | Ictal (n = 8) | Healthy control (n = 12) | P—value |
|--------------------------------------------------------------------------|---------------------|--------------|--------------------------|---------|
| **Age**                                                                  | 34.62 (28.66—40.58) | 36.87 (26.93—46.81) | 30.75 (27.95—33.55) | 0.91    |
| Body mass index (BMI)                                                    | 21.95 (19.84—24.06) | 21.90 (19.59—24.20) | 23.28 (21.39—25.17) | 0.36    |
| Last meal (hours ago)                                                    | 6.67 (3.65—9.68)    | 6.62 (1.64—11.61)  | 3.83 (0.66—6.99)     | 0.21    |
| **Co-morbidities and therapy**                                            |                     |               |                         |         |
| Known other diseases (%)                                                 | 50 (24—75)          | 50 (12—87)    |                         | 1.00    |
| Regular medication (except attack therapy) (%)                            | 31 (7—54)           | 38 (1—73)     |                         | 0.76    |
| Hormonal contraceptives (%)                                               | 37 (12—62)          | 25 (0—57)     | 25 (0—51)               | 0.73    |
| Antimigraine prophylactic therapy (%)                                     | 0                   | 0             |                         |         |
| **Clinical features of the headache**                                    |                     |               |                         |         |
| Disease duration (years)                                                 | 13.18 (8.95—17.41)  | 15.5 (7.98—23.01) |                         | 0.51    |
| Attack frequency (attack/year)                                           | 23.93 (16.65—31.22) | 21.87 (10.95—32.79) |                     | 0.62    |
| Visual analogue scale category (VAS)                                      | 2.68 (2.45—2.92)    | 2.62 (2.26—2.98) |                         | 0.76    |
| Allodynia (%)                                                             | 31 (7—54)           | 50 (12—87)    |                         | 0.38    |
| Chronic pain (%)                                                          | 18 (0—38)           | 12 (0—37)     |                         | 0.70    |
| Menstruation-headache relationship (sensitive) (%)                        | 37 (12—62)          | 37 (1—73)     |                         | 1.00    |
| Migraineurs in the family (%)                                            | 68 (0.45—0.92)      | 62 (26—98)    |                         | 0.76    |
| Regular exercise (%)                                                      | 56 (30—81)          | 62 (26—98)    | 17 (0—39)              | 0.06    |
| **Features of attacks before samplings**                                  |                     |               |                         |         |
| Number of attacks in the previous month                                  | 2.62 (1.4—3.84)     | 0.87 (0.18—1.56) |                         | 0.03    |
| Last attack (days ago)                                                    | 20.25 (3.26—37.23)  | 36.62 (3.38—69.86) |                     | 0.04    |
| Beginning of attack before ictal sampling (hours)                        |                     |               |                         |         |
| Actual VAS                                                               |                     |               |                         |         |
frequency, pain severity, etc. The only significant difference between the interictal and ictal groups was the number of attacks in the previous month and the date of the last attack before sampling (Table 1).

**microRNA signatures of PBMC samples**

When interictal PBMC samples were compared to healthy ones, 31 miRNAs were DE, when significance was tested against a fold change threshold of 1.2 and a p-value threshold of 0.05. 14 miRNAs were upregulated, and 17 were downregulated. Based on the average of fold change and p-value ranks (average rank), hsa-miR-5189-3p, hsa-miR-96-5p, hsa-miR-3613-5p, hsa-miR-99a-3p, and hsa-miR-542-3p were found at the top of the DE miRNA list (Table 2; for further details please see Table S1).

In ictal vs interictal comparison, 25 miRNAs were DE (significance was tested against fold change 1.2 and p-value: 0.05), 15 were upregulated, and 10 were downregulated. Top 5 miRNAs were as follows: hsa-miR-3202, hsa-miR-7855-5p, hsa-miR-6770-3p, hsa-miR-1538, hsa-miR-409-5p (Table 3; for further details please see Table S2).

In ictal samples compared to the healthy group, 31 miRNAs were DE (fold change: 1.2, p-value: 0.05), 22 were upregulated, 9 were downregulated, hsa-miR-1277-5p being at the top of the list (Table S3).

DE miRNAs were visualised on heat maps (Figs. 1 and 2), and samples were clustered based on correlation. They were partitioned into major groups, largely overlapping with the original patient groups. DE miRNAs for ictal vs. healthy interaction were represented on a heat map in Figure S1.

Functional enrichment analysis of DE miRNAs (DE list enrichment) was carried out. GO, and KEGG analysis was performed to link information with functions and utilities of the biological system (Tables 4 and 5). Intercital samples compared to healthy ones show a relation to several GO categories (pathways and processes), including several toll-like receptor signalling pathways, platelet degranulation, cellular response to glucagon stimulus, and alpha-linolenic acid metabolic process.

In the ictal PBMC samples compared to the interictal group, several toll-like receptor signalling pathways and positive regulation of protein insertion into the mitochondrial membrane involved in the apoptotic signalling pathway were altered. Interestingly, regulation of rhodopsin mediated signalling pathway and phototransduction were significantly affected.

KEGG pathway mapping revealed ECM (extracellular matrix)—receptor interaction and GABAergic synapse involvement, characterising interictal samples compared to control samples. TGF-beta) Transforming growth factor β and ErbB (epidermal growth factor receptor) signalling pathways appeared in interictal vs healthy and ictal vs interictal comparisons.

**Table 2** DE miRNAs in interictal PBMC samples compared to healthy ones. Differential expression was tested against a fold change threshold of 1.2 and p-value threshold of 0.05. Average rank was calculated as the mean ranks of miRNAs based on fold change and p-value.

| ID      | Fold change | P-value | Average rank |
|---------|-------------|---------|--------------|
| hsa-miR-5189-3p | 2.59 | 0.0057 | 1 |
| hsa-miR-96-5p  | -2.40 | 0.0032 | 2 |
| hsa-miR-3613-5p | 2.55 | 0.0101 | 3 |
| hsa-miR-99a-3p  | 2.37 | 0.0079 | 4 |
| hsa-miR-542-3p  | 2.40 | 0.0164 | 5 |
| hsa-miR-6803-3p | 2.19 | 0.0162 | 6 |
| hsa-miR-6731-3p | -2.14 | 0.0084 | 7 |
| hsa-miR-577    | -2.17 | 0.0200 | 8 |
| hsa-miR-95-3p  | -2.06 | 0.0184 | 9 |
| hsa-miR-556-3p | -2.18 | 0.0228 | 10 |
| hsa-miR-412-5p | -2.36 | 0.0290 | 11 |
| hsa-miR-5701   | -2.24 | 0.0263 | 12 |
| hsa-miR-3064-5p | 2.10 | 0.0247 | 13 |
| hsa-miR-196a-5p | -2.55 | 0.0450 | 14 |
| hsa-miR-5189-5p | 1.93 | 0.0222 | 15 |
| hsa-let-7i-3p  | -1.82 | 0.0067 | 16 |
| hsa-miR-1277-5p | 2.07 | 0.0402 | 17 |
| hsa-miR-29b-3p | -1.85 | 0.0214 | 18 |
| hsa-miR-4676-3p | 1.87 | 0.0261 | 19 |
| hsa-miR-548j-3p | 1.91 | 0.0453 | 20 |
| hsa-miR-1260b   | 1.78 | 0.0361 | 24 |
| hsa-miR-326    | 1.62 | 0.0027 | 26 |
| hsa-miR-3174   | 1.79 | 0.0480 | 27 |
| hsa-miR-210-3p | 1.77 | 0.0461 | 31 |
| hsa-miR-32-5p  | -1.65 | 0.0373 | 34 |
| hsa-miR-342-3p | -1.60 | 0.0307 | 40 |
| hsa-miR-3607-3p | -1.59 | 0.0381 | 44 |
| hsa-miR-142-5p | -1.54 | 0.0239 | 54 |
| hsa-miR-192-5p | -1.56 | 0.0440 | 57 |
| hsa-miR-155-5p | -1.43 | 0.0186 | 74 |
| hsa-let-7g-5p  | -1.43 | 0.0351 | 76 |
PLEKH3 (pleckstrin homology domain-containing M3), MEF2C (myocyte enhancer factor 2C), BBX (BBX high mobility group box domain containing), ribosomal modification protein RIMKLB (rimK like family member B) and HACE1 (HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1) were significantly downregulated. In contrast, CCN T2 (cyclin T2) and KLHL15 (kelch like family member 15) showed significant upregulation in the interictal group (Table 5). DE miRNAs with their predicted interactions are shown in Fig. 3.

**Fig. 1** Heat map representation of differentially expressed genes in the interictal vs healthy PBMC comparison. Columns represent samples, and rows represent genes. Pearson correlation was respectively calculated between samples and genes, visualised by dendrograms.

**Fig. 2** Heat map representation of differentially expressed genes in the ictal vs interictal comparison. Columns represent samples, and rows represent genes. Pearson correlation was respectively calculated between samples and genes, visualised by dendrograms. Samples from patient “A” in different ictal and interictal periods are marked with respective colors.
Predicted targets with the highest absolute node strength values in ictal vs interictal comparison

In ictal PBMC samples compared to the interictal subgroup, 5665 mRNAs were predicted to be regulated by the 25 significantly DE miRNAs. Among the targets with the highest absolute node strength values, NR3C1 (nuclear receptor subfamily 3 group C member 1) appears with a strength value of 7, GRIA2 (glutamate ionotropic receptor AMPA type subunit 2), and MLLT3 (MLLT3 super elongation complex subunit 2) with a strength value of 6. 32 upregulated targets with a node strength of -2, like FN1 (Fibronectin 1) and CBX5 (Chromobox 5) were detected in ictal-interictal comparison (Table 6). DE miRNAs with their predicted interactions are shown in Fig. 4.

In addition, the intersect of 6781 predicted targets 31 DE miRNAs data in ictal vs healthy comparison and DE mRNAs are enlisted in Table S6. The visualisation of DE miRNAs with their predicted interactions in ictal vs. healthy interaction can be found in Figure S2.

Gene Ontology enrichment analysis of predicted mRNAs

To explore biological processes modified by migraine in headache-free (interictal) period and during headache (ictal), GO enrichment analyses of all predicted mRNAs were performed. The result of the GO enrichment analysis showed that DE miRNA-targeted mRNAs were significantly associated with several metabolic regulation processes and negative regulation of platelet activation when the interictal group was compared to healthy samples. Besides, regulation of nuclear-transcribed mRNA catabolic process, neuron development, and neuron differentiation seem to be affected by migraine (Table 7).

Validation of predicted mRNA targets miRNAs based on mRNA sequencing data

In interictal PBMC samples compared to healthy samples, out of 7012 predicted targets, 54 can also be found in DE mRNA data. In this comparison, 31 targets showed expression changes in the predicted direction, like TNF (tumor necrosis factor), SOCS3 (suppressor of cytokine signalling 3), numerous chemokines such as IL6 (interleukin-6), and SOD2 (superoxide dismutase 2), with a role in oxidative phosphorylation (Table 8). Of 5665 predicted targets, 26 can also be found in DE mRNA data in the ictal-interictal analysis. In this settlement, 12 targets showed expression changes in the predicted direction, e.g., RAB3B, LRRTM2 (Leucine-Rich Repeat Transmembrane Neuronal 2) (Table 9).

Table 3

| ID          | Fold change | P-value | Average rank |
|-------------|-------------|---------|--------------|
| hsa-miR-3202 | 2.94        | 0.0014  | 1            |
| hsa-miR-7855-5p | -2.69   | 0.0033  | 2            |
| hsa-miR-6770-3p | 2.90     | 0.0135  | 3            |
| hsa-miR-1538  | -2.22       | 0.0023  | 4            |
| hsa-miR-409-5p | -2.57     | 0.0072  | 5            |
| hsa-miR-501-3p | -2.16     | 0.0014  | 6            |
| hsa-miR-1299  | 3.53        | 0.0248  | 7            |
| hsa-miR-1271-5p | -2.60    | 0.0187  | 8            |
| hsa-miR-4687-3p | -2.21     | 0.0217  | 9            |
| hsa-miR-4743-5p | -2.07     | 0.0135  | 10           |
| hsa-miR-1277-5p | 2.08      | 0.0184  | 11           |
| hsa-miR-3180-3p | 2.51      | 0.0351  | 12           |
| hsa-miR-4646-5p | -2.18     | 0.0311  | 13           |
| hsa-miR-5581-3p | 2.14      | 0.0251  | 14           |
| hsa-miR-6882-5p | 2.11      | 0.0257  | 15           |
| hsa-miR-449a   | 1.94        | 0.0332  | 16           |
| hsa-miR-4473   | 2.01        | 0.0439  | 17           |
| hsa-miR-4775   | 1.96        | 0.0422  | 18           |
| hsa-miR-33b-3p | -1.92       | 0.0411  | 20           |
| hsa-miR-99b-5p | -1.84       | 0.0242  | 21           |
| hsa-miR-1270   | 1.87        | 0.0328  | 22           |
| hsa-miR-18b-5p | 1.94        | 0.0463  | 23           |
| hsa-miR-6864-5p | 1.90      | 0.0374  | 24           |
| hsa-miR-211-5p | 1.91        | 0.0493  | 25           |
| hsa-miR-590-3p | 1.82        | 0.0392  | 31           |
Fig. 3 (See legend on previous page.)
Discussion

The present results obtained from a self-controlled study design provide the first evidence for disease and headache-specific miRNA patterns in PBMC of migraineurs. Our findings can help to identify key elements of the pathophysiological pathways, determine potential novel diagnostic and prognostic biomarkers and drug targets. The discovery of the small non-coding RNAs [25], together with the use of PBMCs, has offered new opportunities in this area [10].

In the interictal PBMC samples, 31 miRNAs were DE compared to healthy controls, including hsa-miR-5189-3p, hsa-miR-96-5p, hsa-miR-3613-5p, hsa-miR-99a-3p, and hsa-miR-542-3p. hsa-miR-5189-3p closely correlates with spinal cord injury and is part of a set of transcripts proposed to have a role in classifying the disease [85]. The miR-96 and its miR-183 family have been observed to be regulated in diverse regions of the somatosensory nociceptive pathway in different chronic pain conditions in rodents [86]. The miR-183 cluster is distinctly enriched in sensory organs. It may influence the neuronal changes associated with the development and maintenance of chronic pain conditions by coordinate regulating multiple diverse nociceptive genes [87]. Circulating hsa-miR-3613-5p increased in severe axial pain after accident [88] and decreased in endometriosis [89, 90]. Serum hsa-miR-542-3p was found to be a part of miRNA signatures for endometriosis diagnosis [91]. The hsa-miR-99a-3p was downregulated in salivary exosomal miRNAs of burning mouth syndrome patients [92].

Our results revealed GABAergic synaptic changes in both interictal and ictal samples of migraineurs compared to healthy controls. The abnormalities of GABAergic signalling in migraine pathophysiology have been widely investigated in the literature [93]. Serum miRNA results also have suggested that targeting the GABA system might have therapeutic relevance [27]. Interestingly, but not surprisingly, the rhodopsin-mediated signalling pathway and phototransduction were involved as attack specific alterations (ictal-interictal comparison). Photophobia is a light-induced phenomenon linked with migraine and intensifying headache pain [94]. Although migraine research primarily focuses on the affected melanopsin-related pathways [95], it is clear that abnormal light processing is present in these patients. However, the reflection of these alterations in peripheral blood samples could be an exciting question in further research.

Similar to our PBMC results, differentially expressed miR-155 and let-7 g levels related to endothelial functions were described in migraineurs’ serum samples during ictal and interictal periods [96]. Another member of
the let-7 family, let-7b, was found to be downregulated in migraine patients’ PBMC samples [28].

The top DE miRNAs during headache attacks compared to the self-control interictal samples were the following: hsa-miR-3202, hsa-miR-7855-5p, hsa-miR-6770-3p, hsa-miR-1538, hsa-miR-409-5p. Among exosomal miRNAs, hsa-miR-3202 was dysregulated in mild traumatic brain disorders [97], and hsa-miR-409-5p was DE in complex regional pain syndrome [98]. The latest was downregulated after contusion spinal cord injury, while its overexpression could promote recovery [91]. hsa-miR-7855-5p is known to be hypoxia-responsive [99], suggesting a relation to oxidative stress, and hsa-miR-1538 modifies cell response to oxidative stress [100]. hsa-miR-6770-3p decreased in chronic periodontitis as a potential biomarker [92].

In both comparisons, the list of top predicted targets with the highest absolute node strength value consists of a few mRNAs linked to the pathophysiological mechanisms of migraine. GRIA2 and NR3C1, involved

| TermID          | Name                                                                 | Frequency | p-value  | Number of genes | Number of miRNAs |
|-----------------|----------------------------------------------------------------------|-----------|----------|-----------------|------------------|
| GO:0048011      | neurotrophin TRK receptor signalling pathway                         | 0.07      | 1.22E-51 | 161             | 24               |
| GO:0038095      | Fc-epsilon receptor signalling pathway                               | 0.14      | 6.77E-39 | 104             | 24               |
| GO:0035666      | TRIF-dependent toll-like receptor signalling pathway                 | 0.04      | 6.03E-15 | 43              | 20               |
| GO:0034166      | toll-like receptor 10 signalling pathway                             | 0.01      | 4.80E-14 | 38              | 19               |
| GO:0038123      | toll-like receptor TLR1:TLR2 signalling pathway                      | 0.01      | 1.63E-13 | 39              | 20               |
| GO:0034146      | toll-like receptor 5 signalling pathway                              | 0.01      | 1.82E-11 | 38              | 19               |
| GO:0034279      | protein N-linked glycosylation via asparagine                        | 0.13      | 3.52E-07 | 47              | 19               |
| GO:0006921      | cellular component disassembly involved in execution phase of apoptosis | 0.12      | 2.29E-06 | 23              | 19               |
| GO:002576       | platelet degranulation                                               | 0.05      | 2.34E-05 | 32              | 18               |
| GO:0018279      | regulation of defense response to virus by virus                     | 0.01      | 8.27E-04 | 16              | 13               |
| GO:0025872      | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 0.07 | 8.27E-04 | 16 | 16 |
| GO:0035587      | nucleotide-binding domain. leucine rich repeat containing receptor signalling pathway | 0.08 | 1.04E-03 | 18 | 16 |
| GO:0034199      | activation of protein kinase A activity                              | 0.02      | 4.86E-04 | 10              | 8                |
| GO:0071377      | cellular response to glucagon stimulus                               | 0.06      | 5.90E-03 | 18              | 16               |
| GO:0036109      | alpha-linolenic acid metabolic process                              | 0.06      | 6.51E-03 | 7               | 6                |

| TermID          | Name                                                                 | Frequency | p-value  | Number of genes | Number of miRNAs |
|-----------------|----------------------------------------------------------------------|-----------|----------|-----------------|------------------|
| GO:0048011      | neurotrophin TRK receptor signalling pathway                         | 0.07      | 2.39E-44 | 157             | 21               |
| GO:0038095      | Fc-epsilon receptor signalling pathway                               | 0.14      | 2.95E-34 | 102             | 19               |
| GO:0006921      | cellular component disassembly involved in execution phase of apoptosis | 0.12      | 3.28E-10 | 29              | 16               |
| GO:0038123      | toll-like receptor 10 signalling pathway                             | 0.01      | 2.20E-09 | 35              | 15               |
| GO:0038124      | toll-like receptor TLR1:TLR2 signalling pathway                      | 0.01      | 2.20E-09 | 35              | 15               |
| GO:0034166      | toll-like receptor 5 signalling pathway                              | 0.01      | 4.66E-09 | 33              | 15               |
| GO:0034146      | toll-like receptor 5 signalling pathway                              | 0.01      | 3.68E-07 | 33              | 15               |
| GO:0006369      | termination of RNA polymerase II transcription                      | 0.07      | 1.35E-04 | 23              | 14               |
| GO:002576       | platelet degranulation                                               | 0.05      | 3.17E-04 | 31              | 15               |
| GO:0023400      | regulation of rhodopsin mediated signalling pathway                  | 0.06      | 4.62E-04 | 16              | 9                |
| GO:1900740      | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signalling pathway | 0.02      | 2.12E-03 | 18 | 15 |
| GO:0007603      | phototransduction. visible light                                    | 0.07      | 4.18E-03 | 38              | 14               |
| GO:0050690      | regulation of defense response to virus by virus                    | 0.01      | 6.52E-03 | 13              | 8                |
| GO:0034199      | activation of protein kinase A activity                              | 0.02      | 7.95E-03 | 10              | 8                |
in glutamate and glucocorticoid signalling, respectively, appear to be specific to the headache phase in our data set. Our results are supported by the demonstration of glutamatergic neurotransmission changes in trigemino-vascular activation and central sensitisation [101, 102]. However, a case–control study did not find an association between migraine and GRIA2 polymorphisms [103]. DNA methylation of the NR3C1 gene is the focus of epigenetic literature [104, 105]. GWAS studies link the transcription factor MEF2, which was downregulated in our study, to neuroinflammatory processes [106], epilepsy [107], psychological and metabolic features [108, 109].

Pathway analysis pointed out TLR (toll-like receptor) signalling pathways involved in both the headache-free state and headache. TLRs are transmembrane receptors playing a crucial role in innate immune response and inflammation, which activate the NF-κB and interferon regulatory factors resulting in proinflammatory cytokine production like TNFα, IL1, IL6, and IL12. Altered interleukin and TNFα levels in migraine have been demonstrated in the literature [110–112]. Our miRNA target prediction results are in line with these data. IL-6 and TNFα were validated by comparing to mRNA levels demonstrated in our previous paper [11]. Although the involvement of TLR4 signalling in initiating and maintaining migraine-like behaviour in mice and inducing hyperalgesia in rats has been proposed [113–117], this is the first study that links the TLR pathway specifically to migraineurs. In addition, there is evidence suggesting a strong TLR-4/miRNA interplay, which might be a possible target for modern immunotherapy [118].

Among validated targets describing the migraine disease in the attack-free period, EGR1 (early growth response gene 1) was enlisted, which can regulate multiple aspects of synaptic plasticity [119] [120]. Several validated targets line up as regulators and participants of the immune system and inflammatory pathways, like NFKBIA (NFkB inhibitor alpha) and IER3 (early

**Table 6** List of predicted targets up- or downregulated by DE miRNAs in interictal vs healthy and ictal vs interictal comparison, with the highest absolute node strength values. The intersect of predicted targets and DE mRNAs is available in Table S4-6

| Official Symbol | Official Full Name | Node strength | Official Symbol | Official Full Name | Node Strength |
|----------------|-------------------|---------------|----------------|-------------------|---------------|
| Targets predicted to be downregulated |
| CADM2 | cell adhesion molecule 2 | 4 | NR3C1 | nuclear receptor subfamily 3 group C member 1 | 7 |
| PLEKHM3 | pleckstrin homology domain containing M3 | 4 | GRIA2 | glutamate ionotropic receptor AMPA type subunit 2 | 6 |
| MEF2C | myocyte enhancer factor 2C | 4 | MLLT3 | MLLT3 super elongation complex subunit | 6 |
| BBX | BBX high mobility group box domain containing | 4 | | |
| RIMKLB | ribosomal modification protein rimK like family member B | 4 | |
| HACE1 | HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 | 4 | |
| Targets predicted to be upregulated |
| CCNT2 | cyclin T2 | -6 | 32 targets with a node strength of -2 |
| KLHL15 | kelch like family member 15 | -8 | |

(See figure on next page.)

**Fig. 4** Visualisation of miRNA-mRNA interaction network (EntOptLayout) and target prediction analysis (ictal vs interictal) by miRNAtarget.com™. Rectangle and oval-shaped nodes represent miRNAs and mRNA targets of miRNAs, respectively. The node size and colour intensity of mRNA targets change according to node strength values. Down (blue)- and upregulated (red) miRNAs, suggesting a central role of downregulated (light blue) nuclear receptor subfamily 3 group C member 1 (NR3C1) and multiple upregulated (orange) mRNAs. Whole predicted miRNA-target interaction network is shown on panel A. To highlight important miRNA targets, targets with an absolute node strength value less than or equal to 1 (i.e. -1, 0 or 1) presented uniformly smaller and fainter. On panel B, a subnetwork of the whole predicted miRNA-target interaction network is shown, containing only those target mRNAs (marked with a red oval on panel A) and their interacting miRNAs that were validated by RNA sequencing. The same arrangement as in the whole network with a proportional magnification of the target miRNAs was applied.
Fig. 4 (See legend on previous page.)
response 3) [121, 122]. TNFAIP6 (TNF Alpha Induced Protein 6) might be a potential miRNA target with anti-inflammatory properties [59]. NR4A2 (Nuclear Receptor Subfamily 4 Group A Member 2), through the regulation of various signals, inhibits the expression of proinflammatory mediators and plays a neuroprotective role [63]. EGR3 (Early Growth Response 3) is essential for controlling inflammation and antigen-induced immune cell proliferation [123]; it suppresses SOCS1, SOCS3 (cytokine signalling-1 and 3), regulating cytokine or hormone signalling. The enzyme encoded by the SAT1 (Spermidine/Spermine N1-Acetyltransferase 1) gene catalyses the acetylation of spermidine and spermine, thus mediating polyamine metabolism.

### Table 7
Gene Ontology (GO) enrichment analysis (biological processes) of all miRNA targets in interictal vs healthy and ictal vs interictal comparisons. The top ten predicted up-and downregulated processes with the highest fold enrichment values are presented here, where sorting is based on the fold enrichment of the most specific subclasses.

| Intercital vs Healthy | GO biological process | Fold Enrichment | FDR  | GO biological process | Fold Enrichment | FDR  |
|----------------------|-----------------------|-----------------|------|-----------------------|-----------------|------|
| Targets predicted to be downregulated | flavonoid glucuronidation (GO:0052696) | 10.28  | 7.9E-04 | postsynaptic specialization organization (GO:0099084) | 3.47  | 3.09E-02 |
| | negative regulation of cellular glucuronidation (GO:2001030) | 10.28  | 2.04E-03 | regulation of nuclear-transcribed mRNA catabolic process, deamination-dependent decay (GO:1900151) | 3.47  | 3.09E-02 |
| | negative regulation of glucuronosyltransferase activity (GO:1904224) | 10.28  | 2.03E-03 | postsynaptic density organization (GO:0097106) | 3.47  | 3.08E-02 |
| | regulation of glucuronosyltransferase activity (GO:1904223) | 10.28  | 2.02E-03 | negative regulation of smooth muscle cell migration (GO:0014912) | 3.30  | 1.49E-02 |
| | regulation of cellular glucuronidation (GO:2001029) | 9.14  | 3.21E-03 | hippo signalling (GO:0035329) | 2.85  | 3.17E-02 |
| | xenobiotic glucuronidation (GO:0052697) | 8.41  | 1.88E-03 | regulation of mesenchymal cell proliferation (GO:0010464) | 2.72  | 1.91E-02 |
| | flavonoid metabolic process (GO:0009812) | 6.43  | 3.10E-03 | roof of mouth development (GO:0060021) | 2.47  | 7.20E-05 |
| | cellular glucuronidation (GO:00052695) | 6.28  | 1.67E-03 | regulation of smooth muscle cell migration (GO:0014910) | 2.41  | 4.74E-03 |
| | uronic acid metabolic process (GO:0006063) | 5.36  | 2.17E-03 | regulation of dendritic spine morphogenesis (GO:0061001) | 2.41  | 1.85E-02 |
| | glucuronate metabolic process (GO:0019585) | 5.36  | 2.16E-03 | positive regulation of epithelial to mesenchymal transition (GO:0010718) | 2.36  | 2.89E-02 |

| Ictal vs Interictal | GO biological process | Fold Enrichment | FDR  | GO biological process | Fold Enrichment | FDR  |
|---------------------|-----------------------|-----------------|------|-----------------------|-----------------|------|
| Targets predicted to be upregulated | negative regulation of platelet activation (GO:0010544) | 3.35  | 3.79E-02 | regulation of cell projection organization (GO:0031344) | 2.03  | 3.79E-02 |
| | G1 phase (GO:00051318) | 3.28  | 3.00E-02 | neuron development (GO:0048666) | 1.95  | 2.14E-02 |
| | mitotic G1 phase (GO:0000080) | 3.38  | 3.00E-02 | intracellular protein transport (GO:0006886) | 1.79  | 3.90E-02 |
| | regulation of transcription involved in G1/S transition of mitotic cell cycle (GO:0000083) | 3.27  | 1.87E-03 | neuron differentiation (GO:0030182) | 1.78  | 3.58E-02 |
| | response to muscle stretch (GO:0035994) | 3.22  | 2.35E-02 | generation of neurons (GO:0048699) | 1.78  | 1.80E-02 |
| | negative regulation of cyclin-dependent protein kinase activity (GO:1904030) | 3.18  | 6.66E-03 | neurogenesis (GO:0022008) | 1.72  | 1.79E-02 |
| | regulation of sister chromatid cohesion (GO:0007063) | 3.13  | 3.85E-02 | intracellular transport (GO:0046907) | 1.62  | 3.97E-02 |
| | negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736) | 3.11  | 1.12E-02 | cellular macromolecule localization (GO:0070727) | 1.61  | 3.15E-02 |
| | regulation of histone H3-K9 methylation (GO:0005170) | 3.09  | 3.02E-02 | cellular protein localization (GO:0034613) | 1.60  | 3.66E-02 |
| | positive regulation of pri-miRNA transcription by RNA polymerase II (GO:1902895) | 3.05  | 2.47E-03 | nitrogen compound transport (GO:0071705) | 1.56  | 3.40E-02 |
This data underlines our previous findings [11], where we described alterations in spermin and spermidine metabolites in migraineurs’ plasma samples. The role of oxidative stress and mitochondrial dysfunction in migraine susceptibility and headache generation has also been demonstrated in our recent work [11]. Sgk

**Table 8** Common targets, with similar changes in mRNA- and small RNA sequencing data for validation of predictions at mRNA level in interictal vs healthy comparison. Description and pain phenotype matches based on Human Pain Gene [53], Pain Research Forum [54], DisGeNET [55], and GeneCards [56], complemented with other literature data. logFC: logarithm of the fold change of measured mRNA data.

| Target      | logFC | Node Strength | Description                                                                                     | Pain/inflammation related diseases/processes (if applicable)                                                                 |
|-------------|-------|---------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| PLCXD2      | -1.337| 1             | phosphatidylinositol specific phospholipase C X domain containing 2                             | migraine, high pain and high fatigue, cancer pain [53], painful neuropathy [54], rheumatoid arthritis [55], Crohn disease [55]     |
| TNF         | 2.814 | -1            | tumor necrosis factor                                                                          | regulates proteins involved in inflammation [56]                                                                                                                                     |
| EGR1        | 2.616 | -1            | early growth response 1                                                                         | temporomandibular disorder [53]                                                                                                                                                    |
| EREG        | 3.063 | -1            | epiregulin                                                                                      | upregulated by oxidative stress; maturation marker, antiinflammatory effects [57, 58]                                                                                           |
| CD83        | 2.504 | -1            | CD83 molecule                                                                                   | associated with dopaminergic neuron differentiation and dopamine biosynthetic processes [62], neuroinflammation [63] mediates production of inflammatory cytokines [64] |
| NFKBIA      | 1.861 | -1            | NFKB inhibitor alpha                                                                           | cancer pain [53]                                                                                                           |
| IER3        | 1.810 | -1            | immediate early response 3                                                                     | sarcoidosis [55]                                                                                                          |
| TNFAIP6     | 2.464 | -1            | tumor necrosis factor alpha-induced protein 6                                                   | rheumatoid arthritis [59]                                                                                                 |
| ID1         | 1.723 | -1            | inhibitor of DNA binding 1, HLH protein                                                         | response to oxidative stress [60]                                                                                      |
| OSR2        | 1.936 | -1            | odd-skipped related transcription factor 2                                                      | upregulated in mirror image pain in rat CRPS model [61]                                                                    |
| NR4A2       | 1.752 | -1            | nuclear receptor subfamily 4 group A member 2                                                  | associated with dopaminergic neuron differentiation and dopamine biosynthetic processes [62], neuroinflammation [63] mediates production of inflammatory cytokines [64] |
| PLCXD2      | 2.178 | -1            | contactin associated protein-like 3                                                             | Crohn’s Disease [65], chronic pain [66], inflammatory pain [67]                                                        |
| FOSB        | 1.524 | -1            | FosB proto-oncogene, AP-1 transcription factor subunit                                           | neuropathic pain [56]                                                                                                      |
| IL6         | 1.826 | -1            | interleukin 6                                                                                   | antiinflammatory in neuropathic pain [68], alleviates neuroinflammation and neuronal injury [69]                          |
| EGR3        | 1.694 | -1            | early growth response 3                                                                         | regulates cytokine signal transduction [56], chronic pain [66]                                                           |
| DUSP1       | 1.265 | -1            | dual specificity phosphatase 1                                                                  | neuroinflammation [70]                                                                                                      |
| SOCS3       | 1.284 | -1            | suppressor of cytokine signalling 3                                                              | undifferentiated spondylarthritis [71]                                                                                  |
| SAT1        | 1.147 | -1            | spermidine/spermine N1-acetyltransferase 1                                                       | psoriasis, ulcerative colitis, Crohn’s disease, inflammatory bowel disease [55]                                           |
| RGS1        | 1.681 | -1            | regulator of G protein signalling 1                                                              | psoriasis [73]                                                                                                          |
| PLAU        | 1.312 | -1            | plasminogen activator, urokinase                                                                 | non-small cell lung cancer [75]                                                                                           |
| MIPOL1      | 1.252 | -1            | mirror-image polydactyl 1                                                                      | nasopharyngeal carcinoma [72]                                                                                             |
| JUNB        | 1.059 | -1            | JunB proto-oncogene, AP-1 transcription factor subunit                                           | psoriasis [73], Crohn’s disease, inflammatory bowel disease [55]                                                         |
| SGK1        | 0.975 | -1            | serum/glucocorticoid regulated kinase 1                                                          | pain development [74]                                                                                                      |
| MAP3K7CL    | 0.878 | -1            | MAP3K7 C-terminal like                                                                         | non-small cell lung cancer [75]                                                                                           |
| CXCL8 (IL8) | 2.806 | -2            | C-X-C motif chemokine ligand 8 (interleukin 8)                                                   | cancer pain [53]                                                                                                          |
| PLAU        | 1.428 | -2            | plasminogen activator, urokinase receptor                                                       | inflammatory bowel disease [76]                                                                                           |
| DUSP2       | 1.521 | -2            | dual specificity phosphatase 2                                                                  | endometriosis, cancer, immune and inflammatory responses [77]                                                            |
| RBKS        | 1.202 | -2            | ribokinase                                                                                      | psoriasis [78]                                                                                                          |
| GXYLT2      | 1.888 | -3            | glucoside xylosyltransferase 2                                                                 | ulcerative colitis [79]                                                                                                    |
| SOD2        | 1.429 | -4            | superoxide dismutase 2                                                                         | migraine [55]                                                                                                           |
| SOCS1       | 1.033 | -4            | suppressor of cytokine signalling 1                                                              | Crohn’s disease, psoriasis [55]                                                                                           |
(serum- and glucocorticoid-inducible protein kinase) [124] and SOD (superoxide dismutase) [125] increased in the interictal samples when compared to controls, underlining the importance of these pathways. In addition, the ictal vs interictal comparison enlisted downregulation of the transmembrane signalling enzyme NOX5 (NADPH oxidase 5) [119].

Conclusions
We provide here the first miRNA profile of migraineurs in headache-free periods and during attacks compared to healthy controls suggesting potential disease- and pain-specific pathophysiological mechanisms. Predicted mRNA targets of differentially expressed miRNAs confirmed and validated by the transcriptomics analysis reveal the involvement of inflammatory and immune mechanisms, cytokine and chemokine signalling, and oxidative stress.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s10194-022-01478-w.

Additional file 1: Supplementary Table 1. Differentially expressed (DE) miRNA list of PBMC small RNA-seq data of the interictal vs healthy comparison. Supplementary Table 2. Differentially expressed (DE) miRNA list of PBMC small RNA-seq data of the ictal vs interictal comparison. Supplementary Table 3. Differentially expressed (DE) miRNA list of PBMC small RNA-seq data of the ictal vs healthy comparison. Supplementary Table 4. List of intersect of predicted targets up- or downregulated by DE miRNAs and DE mRNAs in interictal vs healthy comparison. Supplementary Table 5. List of intersect of predicted targets up- or downregulated by DE miRNAs and DE mRNAs in ictal vs interictal comparison. Supplementary Table 6. List of intersect of predicted targets up- or downregulated by DE miRNAs and DE mRNAs in ictal vs healthy comparison. Supplementary Figure 1. Heat map visualization of DE miRNAs in ictal vs healthy comparison. Supplementary Figure 2. Visualization of DE miRNAs with predicted interactions in ictal vs healthy interaction.

Acknowledgements
Not applicable

Authors' contributions
Conceptualization: Z.H., K.B., JK, AG, LV, JT, PF. Formal Analysis: J.K., BÁ, BB, WB, AG. Investigation: A.T., B.B., ÅB, TK, JK, BT, UP. Resources: LV, JT, AG, K.B., Z.H. Writing – Original Draft Preparation: A.T., B.B., AB, JK, UP, WB, KB, Z.H. Writing – Review and Editing: A.T., TK, JK, PU, WB, AG, BT, JT, PF, LV, PF, KB, Z.H. Visualization: A.T., B.B., AB, JK. Supervision: Z.H., KB, AG, PF, LV, JT. Funding Acquisition: Z.H., KB, AG, PF, LV, JT. The author(s) read and approved the final manuscript.

Table 9 Common targets, with similar changes in mRNA- and small RNA sequencing data for validation of predictions at mRNA level in ictal vs interictal comparison. Description and pain phenotype matches based on Human Pain Gene [53], Pain Research Forum [54], DisGeNET [55], and GeneCards [56], complemented with other literature data. logFC: logarithm of the fold change of measured mRNA data

| Target     | logFC | Node strength | Description                                             | Pain/inflammation related disease/processes (if applicable)                                                                 |
|------------|-------|---------------|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| RAB3B      | -1.370| 3             | RAB3B, member RAS oncogene family                       | psoriasis [56], multiple sclerosis [79]                                                                                  |
| LRRTM2     | -1.051| 2             | leucine rich repeat transmembrane neuronal 2            | excitatory synaptic transmission [80], AMPA receptor transmission [81], oxidative stress [82]                             |
| NOX5       | -1.051| 1             | NADPH oxidase 5                                         | oxidative stress [82]                                                                                                      |
| FAT3       | -1.003| 1             | FAT atypical cadherin 3                                | neuropathy [55]                                                                                                            |
| CBARP      | -0.955| 1             | CACN subunit beta associated regulatory protein         | Negatively regulates voltage-gated calcium channels [56], epilepsy [66], inhibits Notch signalling in neural stem cells, thereby opposing their self-renewal and promoting neurogenesis [56] |
| BEND6      | -0.890| 1             | BEN domain containing 6                                | microglia activation in neurodegenerative diseases [83], upregulated in enhanced pain sensitivity [62]                   |
| RPS27A     | -0.675| 1             | ribosomal protein S27a                                  |brain injury, ischemia [66]                                                                                                 |
| TBCA       | -0.639| 1             | tubulin folding cofactor A                             | transcriptional regulation [56]                                                                                                |
| FRG1B      | -0.620| 1             | FSHD region gene 1 family member B, pseudogene         | transcription factor [56], potential candidate gene for aging in women [84], cellular proliferation [56]                   |
| ZNF730     | 1.175 | -1            | zinc finger protein 730                                | transcription factor [56], potential candidate gene for aging in women [84], cellular proliferation [56]                   |
| ZNF704     | 0.967 | -1            | zinc finger protein 704                                | transcription factor [56], potential candidate gene for aging in women [84], cellular proliferation [56]                   |
| MKI67      | 0.826 | -1            | marker of proliferation Ki-67                          | transcription factor [56], potential candidate gene for aging in women [84], cellular proliferation [56]                   |

Abbreviations
ANOVA: Analysis of variance; BMI body mass index; CGRP: Calcitonin gene-related peptide; DE: Differentially expressed; EDTA: Ethylenediaminetetraacetic acid; FC: Fold change; FDR: False discovery rate; GO: Gene Ontology; GWAS: Genome-wide association studies; KEGG: Kyoto Encyclopedia of Genes and Genomes; PACAP: Pituitary adenylate cyclase-activating polypeptide; PBMC: Peripheral blood mononuclear cells; TNF: Tumor necrosis factor; VAS: Visual analogue scale.
Funding
Open access funding provided by University of Pécs. This research was supported by National Brain Research Program of University of Pécs (2017–1.2.1-NKP-2017–00002 (NAP-2), Chronic Pain Research Group), Gazdaságfejlesztés és Innovaációs Operatív Program (Economy Development and Innovation Operative Programme) (GINOP-2.3.2–15–2016–00050 (Peptidergic Signalling in Health and Disease; PEPSYS), GINOP 2.3.2–15–2016–0034, Emberi Éröfförás Operatív Program (Human Resource Operative Programme) (EFOP) 3.6.2–16–2017–00008 (2017–2019), EFOP-3.6.1–16–2016–00004, TUDFO/47138–1/2019-ITM and National Research Development and Innovation Office of Hungary (NKFI) grant OTKA FK135287, OTKA-138125-K and NKVP–1–2016–0017 National Heart Program. This study was also financed by the Thematic Excellence Programme (2020–4.1.1–TKP2020) of the Ministry for Innovation and Technology in Hungary, within the framework of the Therapeutic Development and Bioimaging thematic programmes of the Semmelweis University. A.G. and J.K. were supported by the grants GINOP-2.3.4–15–2016–00010, GINOP-2.3.1–20-2020–00001 and Educating Experts of the Future: Developing Bioinformatics and Biostatistics competencies of European Biomedical Students (BECOMING, 2019–1-HU01-KA203-061251). B.Á. was supported by the New National Excellence Programme of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund (UNKP–20–4-I-SZEP-7, UNKP–21–4-II-SE–18). Bioinformatics infrastructure was supported by ELIXIR Hungary (http://elixir-hungary.org/).

Availability of data and materials
All RNA-Seq data sets generated as part of this study will be publicly available at the European Nucleotide Archive (https://www.ebi.ac.uk/ena), under accession number PRJEB46142.

Declarations

Ethics approval and consent to participate
The study was approved by the National Public Health Center, Ministry of Human Capacities of Hungary (28324–5/2019/ELIC). All study participants gave their written informed consent in accordance with the Declaration of Helsinki.

Consent for publication
not applicable.

Competing interests
The authors disclose no conflicts of interest.

Author details
1 Department of Pharmacology and Pharmacotherapy, Medical School & Szentagothai Research Centre, Molecular Pharmacology Research Group, Centre for Neuroscience, University of Pécs, Pécs, Hungary. 2 Cardiometabolic and MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. 3 Pharmahungary Group, Szeged, Hungary. 4 MTA-SZTE Neuroscience Research Group, University of Szeged, Szeged, Hungary. 5 Faculty of Health Sciences and Social Studies, University of Szeged, Szeged, Hungary. 6 Szentagothai Research Centre, Bioinformatics Research Group, Genomics and Bioinformatics Core Facility, University of Pécs, Pécs, Hungary. 7 Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary. 8 PharmInVivo Ltd., Pécs, Hungary. 9 Department of Pharmacology and Pharmacotherapy, University of Pécs Medical School, Szigeti út 12, 7624 Pécs, Hungary.

Received: 12 June 2022 Accepted: 9 August 2022
Published online: 02 September 2022

References
1. Bernstein C, Burstein R (2012) Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology. J Clin Neurol 8:89. https://doi.org/10.3988/jcn.2012.8.2.89
2. Bruno PP, Carpinio F, Carpio G, Zicari A (2007) An overview on immune system and migraine. Eur Rev Med Pharmacol Sci 11:245–248
3. Conti P, D’Ovidio C, Conti C, Gallenga CE, Laurantino D, Caraffa A et al (2019) Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Eur J Pharmacol 844:87–94. https://doi.org/10.1016/j.ejphar.2018.12.004
4. Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L (2015) Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Drug Targets 14:540–553. https://doi.org/10.2174/17812731466615042914234
5. Tuka B, Szabó N, Toth E, Kincses ZT, Párdatz A, Szok D et al (2016) Release of PACAP-38 in episodic cluster headache patients - an exploratory study. J Headache Pain 17:69. https://doi.org/10.1186/s10194-016-0660-7
6. Edvinsson L, Haanes KA, Warfvinge K (2019) Does inflammation have a role in migraine? Nat Rev Neuro 15:483–490. https://doi.org/10.1038/s41588-019-0216-y
7. Lisciki M, D’Ottilio K, Ericpium M, Schoenen J, Magis D (2018) Sunlight irradiance and habituation of visual evoked potentials in migraine: The environment makes it mark. Cephalalgia 38:1351–1360. https://doi.org/10.1177/03331024177330128
8. Rollins B, Martin MV, Morgan L, Vawter MP (2010) Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 153B:919–936. https://doi.org/10.1002/ajmg.b.31062
9. Sullivan PF, Fan C, Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141B:261–268. https://doi.org/10.1002/ajmg.b.30272
10. Mosaalaei M, Ehtesham N, Rahimov S, Saghi M, Vatandoost N, Khosravi S (2020) PBMCs: A new source of diagnostic and prognostic biomarkers. Arch Physiol Biochem 61:1–7. https://doi.org/10.1080/19814552.2020.1752257
11. Aczel T, Körtési T, Kun J, Urbán P, Bauer W, Herczeg R et al (2021) Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis. J Headache Pain 22:117. https://doi.org/10.1186/s10194-021-01285-9
12. Bár C, Thurn T, de Gonzalo-Calvo D (2019) Circulating miRNAs as mediators in cell-to-cell communication. Epigenomics 11:111–113. https://doi.org/10.2217/epi-2018-0183
13. Velu VK, Ramesh R, Srinivasa AR (2012) Circulating MicroRNAs as Biomarkers in Health and Disease. J Clin Diagn Res 6:179–180. https://doi.org/10.2174/156652411794859250
14. Vrijens K, Bollati V, Nawrot TS (2015) MicroRNAs as Potential Signatures of Environmental Exposure or Effect: A Systematic Review. Environ Health Perspect 123:399–411. https://doi.org/10.1289/ehp.1408459
15. Hanna J, Hosain GS, Kocerha J (2019) The Potential for microRNA Therapeutics and Clinical Research. Front Genet 10:478. https://doi.org/10.3389/fgene.2019.00478
16. Perrino C, Barabási A-L, Condorelli G, Davidson SM, De Windt L, Dimmelmer S et al (2017) Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res 113:725–736. https://doi.org/10.1093/cvr/cvx070
17. Makkos A, Ágg B, Petrovich B, Varga Z, Görbe Á, Ferdinandy P (2021) Systematic review and network analysis of microRNAs involved in cardioprotection against myocardial ischemia/reperfusion injury and infarction: Involvement of redox signalling. Free Radic Biol Med 172:237–251. https://doi.org/10.1016/j.freeradbiomed.2021.04.034
18. Bengis P, Kiss K, Ágg B, Baán JA, Agoston G, Varga A et al (2019) Sensory Neuritis Affects Cardiac miRNA Expression Network Targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2 miRNAs. Int J Mol Sci 20:6991. https://doi.org/10.3390/ijms20040991
19. Kress M, Hurtenhofer A, Landry M, Kuner R, Faveaunet A, Greenberg DS et al (2013) microRNAs in nociceptive circuits as predictors of future clinical applications. Front Mol Neurosci 6:33. https://doi.org/10.3389/fnmol.2013.00033
21. Andersen HH, Duroux M, Gazerani P (2014) MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions. Neurobiol Dis 71:159–168. https://doi.org/10.1016/j.nbd.2014.08.003
22. López-González WJ, Landry M, Faveureaux A (2017) MicroRNA and chronic pain: From mechanisms to therapeutic potential. Pharmacol Ther 180:1–15. https://doi.org/10.1016/j.pharmthera.2017.06.001
23. Cheng Y, Dong L, Zhang J, Zhao Y, Li Z (2018) Recent advances in microRNA detection. Analyst 143:1758–1774. https://doi.org/10.1039/C7AN01906A
24. Benešova S, Kubista M, Václavík L (2021) Small RNA-Sequencing: Approaches and Considerations for miRNA Analysis. Diagnostics 11:964. https://doi.org/10.3390/diagnostics11060964
25. Gazerani P (2019) Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment. Mol Diag Ther 23:681–694. https://doi.org/10.1007/s12035-019-00428-8
26. Ahmad L, Demartini C, Corrado M, Vaghi G, Piella EM, Allena M et al. (2021) Expression of Selected microRNAs in Migraine: A New Class of Possible Biomarkers of Disease? Processes 9:2199. https://doi.org/10.3390/pp91221199
27. Andersen HH, Duroux M, Gazerani P (2016) Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain–Free Periods. Mol Neurobiol 53:1494–1500. https://doi.org/10.1007/s12035-015-9106-5
28. Tafuri E, Santovito D, de Nardis V, Marcantonio P, Paganelli C, Affaitati G et al. (2015) MicroRNA profiling in migraine patients without aura. Pilot study. Ann Med 47:468–473. https://doi.org/10.1097/01.0MR.0000428905.2015.1071871
29. Vila-Pueyo M, Fernández-Morales J, Torres-Ferrus M, Álvarez-Sabin J, Pozo-Rosich P (2014) EHMT1-0361. Lack of differences in microcircuit expression profiles of blood cells in migraine. J Headache Pain 15:15H.
30. https://doi.org/10.1186/1129-2377-15-51-H3
31. Pozo-Rosich P (2022) microRNA expression profile in migraine: the microMIG study. Available: https://www.migratedisorders.org/wp-content/uploads/2019/09/microMIG-MRF-report-2019.pdf [cited 28 Mar 2022].
32. Headache Classification Committee of the International Headache Society (IH5) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/03331024171082938
33. Aczél T, Keckes A, Kun J, Szenthe K, Bánáti F, Szathmary S et al. (2020) MicroRNA interactome analysis predicts post-transcriptional regulation of major protein complexes in protein-protein interaction and signalling networks. Bioinformatics 35:4490–4492. https://doi.org/10.1093/bioinformatics/btz605
34. Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagiannis D, Vlachos IS et al. (2019) Clinical potential of functional microRNA targets. Nucleic Acids Res 48:D127–D131. https://doi.org/10.1093/nar/gky007
35. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36:D149–153. https://doi.org/10.1093/nar/gkm995
36. Ágg B, Csázas Á, Szalay-Bekó M, Veres DV, Mizsei R, Ferdinandy P et al. (2019) The EnGoPlays Cytoscape plug-in for the efficient visualization of major protein complexes in protein-protein interaction and signalling networks. Bioinformatics 35:4490–4492. https://doi.org/10.1093/bioinformatics/btx627
37. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504. https://doi.org/10.1101/gr.123903
38. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. (2000) Gene ontology: tool for the unification of biology. Gene Ontol Consortium Nat Genet 25:25–29. https://doi.org/10.1038/75556
39. Gene Ontology Consortium (2021) The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res 49:D325–D334. https://doi.org/10.1093/nar/gkaa1173
40. Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD (2019) Panther version 14: more genomes, a new Panther GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res 47:D419–D426. https://doi.org/10.1093/nar/gko1038
41. Carbon S, Mungall C. Gene Ontology Data Archive. Zenodo. 2018. https://doi.org/10.5281/zenodo.4081749
42. Human Pain Genetics Database | Pain Research Forum. Available: https://humanpangenetics.org/hpgdb/ [cited 15 Jul 2021].
43. Pain Gene Resource | Pain Research Forum. Available: https://www.painresearchforum.org/resources/pain-gene-resource [cited 15 Jul 2021].
44. Piñero J, Ramírez-Anguita JM, Saich-Pitarach J, Ronzano F, Centeno E, Sanz F et al. (2020) The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 48:D419–D425. https://doi.org/10.1093/nar/gko1021
45. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Gene Sequence Analyses. Current Protocols Bioinformatics. 2016;54:1.30.1–1.30.33. doi:10.1002/cpbi.5
46. Pazmandi K, Agod Z, Kumar BV, Szabo A, Fekete T, Sogor V et al. (2014) Oxidative modification enhances the immunomodulatory effects of extracellular mitochondrial DNA on plasma/erythrocytoid dendritic cells. Free Radical Biol Med 77:281–290. https://doi.org/10.1016/j.freeradbiomed.2014.09.028
47. McGarry T, Biniecka M, Veale DJ, Fearon U (2018) Hypoxia, oxidative stress and inflammation. Free Radical Biol Med 125:15–24. https://doi.org/10.1016/j.freeradbiomed.2018.03.042
48. Day AJ, Milner CM (2019) TSG-6: A multifunctional protein with anti-stress and inflammation. Free Radical Biol Med 125:15–24. https://doi.org/10.1016/j.freeradbiomed.2018.03.042
49. Bensellam M, Montgomery MK, Luzunaga J, Chan JY, Laybutt DR (2015) Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant response in mouse beta cells. Diabetologia 58:758–770. https://doi.org/10.1007/s00125-015-3503-1
50. Nie H, Liu B, Yin C, Chen R, Wang J, Zeng D et al. (2021) Gene Expression Profiling of Contralateral Dorsal Root Ganglia Associated with...
Mirror-Image Pain in a Rat Model of Complex Regional Pain Syndrome Type-I. J Pain Res 14:2739–2756. https://doi.org/10.2147/JPR.S323722

Guo Y-P, Zhi Y-R, Liu T-T, Wang Y, Zhang Y (2019) Global Gene Knockout of Kcnq3 Enhances Pain Sensitivity and Exacerbates Negative Emotions in Rats. Front Mol Neurosci 12.5. https://doi.org/10.3389/fnmol.2019.00005

Jakaria M, Haque ME, Cho D-Y, Azam S, Kim I-S, Choi D-K (2019) Molecular Insights into NRRA2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death. Mol Neurobiol 56:5799–5814. https://doi.org/10.1007/s12035-019-1487-4

Dai Y, Oki S, Otsawa T, Hohjich H, Miyake S, Yamamura T (2008) Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediate production of inflammatory cytokines. Proc Natl Acad Sci U S A 105:8381–8386. https://doi.org/10.1073/pnas.0803454105

Qiao YQ, Huang ML, Zheng Q, Wang TR, Xu AT, Cao Y et al (2015) CNTF-mediated Microglial Polarization toward M2 Phenotype in the Medial Prefrontal Cortex of Neuropathic Pain Rats via Inhibition of MAPK Pathway. ACS Chem Neurosci 12:966–978. https://doi.org/10.1021/acschemneuro.0c00567

Lui-L-P, Zhang J, Bu L, Li-W-Q, Wang Y-S (2020) Upregulation of JHMD1-MAP1A alleviates neuroinflammation and neuronal injury via targeting mir-101-3p/DUSP1 in spinal cord after bRALX injury. Int Immunopharmacol 89:106962. https://doi.org/10.1016/j.intimp.2020.106962

Zahedi K, Brooks M, Barone S, Rahmati N, Murray Stewart T, Dunworth M et al (2020) Ablation of polyamine catabolic enzymes provokes Purkinje cell damage, neuroinflammation, and severe ataxia. J Neuroinflammation 17:301. https://doi.org/10.1186/s12974-020-01955-6

Gui J, Wei Y-L, Wei JCC, Huang F, Jan M-S, Centola M et al (2009) Identification of NRGI as a candidate biomarker for undiscovered spondyloarthrits by genome-wide expression profiling and real-time polymerase chain reaction. Arthritis Rheum 60:3269–3279. https://doi.org/10.1002/art.24968

Lee MML, Cheung AKL, Kwok TCT, Lung ML (2020) Functional characterization of a controller of microglia activation in triggering neurodegenerative diseases. PLoS ONE 15:e0239219. https://doi.org/10.1371/journal.pone.0239219

Scheipers L, Sanders J, Singh J, Kammerer CM, Barmada MM, Matteini AM et al (2015) Genome-Wide Association Study and Linkage Analysis of the Healthy Aging Index. The Journals of Gerontology: Series A 70:1003–1008. https://doi.org/10.1093/gerona/gqv006

Chen Q, Zhao Z, Yin G, Yang C, Wang D, Feng Z et al (2021) Identification and analysis of spinal cord injury subtypes using weighted gene co-expression network analysis. Ann Transl Med 9:466. https://doi.org/10.21037/atm.2021.03-21

Bali KK, Kuner R (2014) Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol Med 20:437–448. https://doi.org/10.1016/j.molmed.2014.05.006

Aldrich BT, Frakes EP, Kasuya J, Hammond DL, Kitamoto T (2009) Changes in expression of sensory organ-specific microRNAs in rat dorsal root ganglia in association with mechanical hypersensitivity induced by spinal nerve ligation. Neuroscience 164:711–725. https://doi.org/10.1016/j.neuroscience.2009.08.033

Linnstaedt SD, Walker MG, Parker JS, Yeh E, Sons RL, Zimny E, et al. MicroRNA Circulating in the Early Aftermath of Motor Vehicle Collision Predict Persistent Pain Development and Suggest a Role for microRNA in Sex-Specific Pain Differences. Mol Pain 2015:11: s2990–015–0069–3. doi:10.1186/s12990-015-0069-3

Borghese B, Zondervan KT, Abrao MS, Chapron C, Vaiman D (2017) Recent insights on the genetics and epigenetics of endometriosis. Clinical Genet 91:254–264. https://doi.org/10.1111/cge.12897

Adam Worku D. The Role of Biomarkers in the Early Diagnosis of Endometriosis. IGRWH. 2017;1. https://doi.org/10.31031/IGRWH.2017.01.000512

Wang W-T, Zhao Y-N, Han B-W, Hong S-J, Chen Y-Q (2013) Circulating MicroRNAs Identified in a Genome-Wide Serum MicroRNA Expression Analysis as Noninvasive Biomarkers for Endometriosis. J Clin Endocrinol Metab 98:281–289. https://doi.org/10.1210/jc.2012-2415

Kim K-Y, Byun J-S, Jung J-K, Choi J-K (2019) Profiling of Salivary Exosomal Micro RNAs in Burning Mouth Syndrome Patients. J Oral Med Pain 44:25–30. https://doi.org/10.4147/jomp.2019.44.1.25

D’Andrea G, Granella F, Cataldini M, Verdelli F, Balbi T (2001) GABA and glutamate in migraine. J Headache Pain 2:s57–s60. https://doi.org/10.1186/101940170011

Noseda R, Copenhagen D, Burstein R (2019) Current understanding of photophobia, visual networks and headaches. Cephalalgia 39:1623–1634. https://doi.org/10.1177/0333102418784750

Zele AJ, Day A, Adhikari P, Feigl B (2021) Melanopsin hypersensitivity dominates interictal photophobia in migraine. Cephalalgia 41:217–226. https://doi.org/10.1177/0333102420963850

Cheng C-Y, Chen S-P, Liao Y-C, Fu H-J-L, Wang Y-F, Wang S-J (2018) Elevated circulating endothelial-specific microRNAs in migraine patients: a pilot study. Cephalalgia 38:1585–1591. https://doi.org/10.1177/03331024187742375

Devoto C, Lai C, Qu-B X, Guedes VA, Leete J, Wilde E et al. Experimental microRNA in military personnel with mild traumatic brain injury: preliminary results from the chronic effects of neurotrauma consortium biomarker discovery project. J Neurotrauma 37:2482–2492. https://doi.org/10.1089/neu.2019.6933

McDonald MK, Tian Y, Qureshi RA, Gormley M, Ertel A, Gao R et al (2014) Functional significance of macrophage-derived exosomes in...
inflammation and pain. Pain 155:1527–1539. https://doi.org/10.1016/j.
pain.2014.04.029
99. Shih C-H, Chuang L-L, Tsai M-H, Chen L-H, Chuang EY, Lu T-P et al (2021)
Hypoxia-Induced MALAT1 Promotes the Proliferation and Migration of
Breast Cancer Cells by Sponging miR-306-5p. Spor. Front Oncol 11:689151.
https://doi.org/10.3389/fonc.2021.689151
100. Pallarès-Albanell J, Zomeño-Abellán MT, Escaramís G, Pantano L,
Soriano A, Segura MF et al (2019) A High-Throughput Screening Identifies
MicroRNA Inhibitors That Influence Neuronal Maintenance and/or
Response to Oxidative Stress. Mol Ther Nucleic Acids. 17:374–387.
https://doi.org/10.1038/s41397-019-003.007
101. Hoffmann J, Charles A (2018) Glutamate and Its Receptors as Therapeu-
tics Targets for Migraine. Neurotherapeutics 15:361–370. https://doi.org/
10.1007/s13313-018-0166-6
102. Ramadan NM (2003) The link between glutamate and migraine. CNS
Spectr 8:446–449. https://doi.org/10.1089/092590018757
103. Gasparini CF, Sutherland HG, Haupt LM, Griffiths LR (2014) Genetic
Analysis of GRIA2 and GRIA4 Genes in Migraine: Headache J Head Face
Pain 5:303–312. https://doi.org/10.1111/head.12234
104. Aroke EN, Joseph PV, Roy A, Overstreet DS, Tollefsbol TO, Vance DE et al
(2020) Role of microRNA-374-3p in the Regression of Human Breast
Cancer Cells by Sponging MiR-306-5p. Front Oncol 11:658151.
105. Berretta E, Guida E, Forni D, Provenzi L (2021) Glucocorticoid receptor
fines MicroRNA Inhibitors That Influence Neuronal Maintenance and/
Response to Oxidative Stress. Mol Ther Nucleic Acids. 17:374–387.
https://doi.org/10.1038/s41397-019-003.007
106. Zhang Z-G, Li Y, Ng CT, Song Y-Q (2015) Inflammation in Alzheimer's
Disease and Molecular Genetics: Recent Update. Arch Immunol Ther
Exp (Warsz) 63:333–344. https://doi.org/10.1016/j.jmir.2019.05.067
107. Borlot F, Whitney R, Cohn RD, Weiss SK (2019) MEF2C-related epilepsy:
Delineating the phenotypic spectrum from a novel mutation and litera-
ture review. Seizure 67:86–90. https://doi.org/10.1016/j.seizure.2019.03.
015
108. Morris J, Bailey MES, Baldassarre D, Cullen B, de Faire U, Ferguson A et al
(2019) Genetic variation in CADM2 as a link between psycholog-
ical traits and obesity. Sci Rep 9:7339. https://doi.org/10.1038/s41598-
019-43861-9
109. Yan X, Wang Z, Schmidt V, Gauer A, Willnow TE, Heining M et al (2018)
Cadm2 regulates body weight and energy homeostasis in mice. Molec.
ular Metabolism 8:180–188. https://doi.org/10.1016/j.molmet.
2017.11.010
110. Covelli V, Massari F, Fallacara C, Munno I, Pellegrino NM, Jirillo E et al
(1991) Increased spontaneous release of tumor necrosis factor-alpha
in cachectin in headache patients. A possible correlation with plasma
endothetoxin and hypothalamic-pituitary-adrenal axis. Int J Neurosci
61:53–60. https://doi.org/10.3109/00207459109896270
111. Perini F, D’andrea G, Galloni E, Pignatelli F, Billo G, Alba S et al (2005)
Plasma cytokine levels in migraineurs and controls. Headache J Head Face
Pain 45:926–931
112. Uzar E, Evliyaoglu O, Yucel Y, Cevik MU, Acar A, Guzel I, et al. (2011)
Serum cytokine and pro-brain natriuretic peptide (BNP) levels in
patients with migraine. Eur Rev Med Pharmacol Sci 15:1111–1116.
113. Ashayeri Ahmadabadi R, Khaleghi Ghadiri M, Gorgi A (2020) The role of
Toll-like receptor signaling pathways in cerebrovascular disorders:
the impact of spreading depolarization. J Neuroinflammation 17:108.
https://doi.org/10.1186/s12974-020-01785-5
114. Bruno K, Woller SA, Miller YL, Yaksh TL, Wallace M, Beaton G et al (2018)
Targeting Toll-like receptor-4 (TLR4) – emerging therapeutic target for
persistent pain states. Pain 159:1908–1915. https://doi.org/10.1097/j.
pain.0000000000001306
115. Lagacina MJ, Watkins LR, Grace PM (2018) Toll-like receptors and their
role in persistent pain. Pharmacol Ther 184:145–158. https://doi.org/
10.1016/j.pharmthera.2017.10.006
116. Ramachandran R, Wang Z, Saavedra C, DiNardo A, corr M, Powell SB
et al (2019) Role of Toll-like receptor 4 signaling in mast cell-mediated
migraine pain pathway. Mol Pain 15:1744806918754612.
117. Xu M, Ran Y, He Z, Zhang M, Hu G, Tang W et al (2018) Inhibition of toll-
like receptor 4 alleviates hyperalgesia induced by acute dural inflamma-
tion in experimental migraine. Mol Pain 14:1744806918754612.
https://doi.org/10.1177/1744806918754612
118. Litak J, Grochowski C, Litak J, Osuchowska I, Gosik K, Radzikowska E
et al (2020) TLR-4 Signaling vs. immune checkpoints, mirnas molecules,
cancer stem cells, and wingless-signaling interplay in glioblastoma
multiforme-future perspectives. Int J Mol Sci 21(9):3114. https://doi.org/
10.3390/ijms21093114
119. Ducot F, Kabbaj M (2017) The Role of Early Growth Response 1 (ERG1)
in brain plasticity and neuropsychiatric disorders. Front Behav Neurosci
11:35. https://doi.org/10.3389/fnbeh.2017.00035
120. Sosthenes MCK, Diniz DG, Roodseelaar J, Abadie-Guedes R, de Siqueira
Mendes FdCC, Fernandez TN et al (2019) Stereological Analysis of Early
Gene Expression Using Egr-1 Immunolabeling After Spreading Depres-
sion in the Rat Somatosensory Cortex. Front Neurosci 13:1020. https://
doi.org/10.3389/fnins.2019.01020
121. Arlt A, Schäfer H (2011) Role of the immediate early response 3 (I3R)
gene in cellular stress response, inflammation and tumorigenesis. Eur J
Cell Biol 90:545–552. https://doi.org/10.1007/s00005-010-0006-2
122. Mitchell S, Varga J, Hoffmann A (2016) Signaling via the NFκβ system.
Wiley Interdiscip Rev Syst Biol Med 8:227–241. https://doi.org/10.1002/
wbi.1331
123. Taefehshokr S, Key Y, Khakpour M, Dadebighlu P, Ovesni A (2017) Early
growth response 2 and Egr3 are unique regulators in immune system.
Central Eur J Immunol 42:205–209. https://doi.org/10.5114/cej.2017.
09363
124. Leong MILL, Mayar AC, Kim B, O'Yeefe BA, Firestone GL (2003) Expression
of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a
cell survival response to multiple types of environmental stress stimuli
in mammary epithelial cells. J Biol Chem 278:5871–5882. https://doi.
org/10.1074/jbc.M211649200
125. Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J (2019) The metabo-
lic face of migraine - from pathophysiology to treatment. Nat Rev Neurol
15:627–643. https://doi.org/10.1038/s41582-019-0255-4

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions